4th Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
CHRISTOPHER J TOPOLESKI —

Contacted: HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); SENATE; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1800 (114th), H.R. 3049 (114th)

Medicare/Medicaid MMM

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
CHRISTOPHER J TOPOLESKI —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE; Government Accountability Office (GAO); Health & Human Services, Dept of (HHS)

Bills named: H.R. 3648 (114th), S. 314 (114th), H.R. 6 (114th), H.R. 592 (114th)

Pharmacy PHA

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Spoke at public meetings on GDUFA and BSUFA. Communication with GAO on drug shortages.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
CHRISTOPHER J TOPOLESKI —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.